S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.37 (+1.01%)
AAPL   142.89 (+1.38%)
MSFT   245.97 (+0.65%)
META   115.72 (+1.57%)
GOOGL   94.02 (-0.97%)
AMZN   90.20 (+1.97%)
TSLA   173.71 (-0.19%)
NVDA   165.24 (+2.51%)
NIO   13.49 (+7.23%)
BABA   92.94 (+5.22%)
AMD   70.42 (+0.40%)
T   19.33 (+0.16%)
MU   54.93 (+2.06%)
CGC   3.22 (-0.62%)
F   13.15 (+0.38%)
GE   85.34 (+0.40%)
DIS   92.71 (+0.61%)
AMC   6.33 (+4.63%)
PYPL   75.03 (+0.82%)
PFE   50.52 (+0.56%)
NFLX   310.21 (+0.58%)
S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.37 (+1.01%)
AAPL   142.89 (+1.38%)
MSFT   245.97 (+0.65%)
META   115.72 (+1.57%)
GOOGL   94.02 (-0.97%)
AMZN   90.20 (+1.97%)
TSLA   173.71 (-0.19%)
NVDA   165.24 (+2.51%)
NIO   13.49 (+7.23%)
BABA   92.94 (+5.22%)
AMD   70.42 (+0.40%)
T   19.33 (+0.16%)
MU   54.93 (+2.06%)
CGC   3.22 (-0.62%)
F   13.15 (+0.38%)
GE   85.34 (+0.40%)
DIS   92.71 (+0.61%)
AMC   6.33 (+4.63%)
PYPL   75.03 (+0.82%)
PFE   50.52 (+0.56%)
NFLX   310.21 (+0.58%)
S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.37 (+1.01%)
AAPL   142.89 (+1.38%)
MSFT   245.97 (+0.65%)
META   115.72 (+1.57%)
GOOGL   94.02 (-0.97%)
AMZN   90.20 (+1.97%)
TSLA   173.71 (-0.19%)
NVDA   165.24 (+2.51%)
NIO   13.49 (+7.23%)
BABA   92.94 (+5.22%)
AMD   70.42 (+0.40%)
T   19.33 (+0.16%)
MU   54.93 (+2.06%)
CGC   3.22 (-0.62%)
F   13.15 (+0.38%)
GE   85.34 (+0.40%)
DIS   92.71 (+0.61%)
AMC   6.33 (+4.63%)
PYPL   75.03 (+0.82%)
PFE   50.52 (+0.56%)
NFLX   310.21 (+0.58%)
S&P 500   3,970.59 (+0.93%)
DOW   33,880.02 (+0.84%)
QQQ   283.37 (+1.01%)
AAPL   142.89 (+1.38%)
MSFT   245.97 (+0.65%)
META   115.72 (+1.57%)
GOOGL   94.02 (-0.97%)
AMZN   90.20 (+1.97%)
TSLA   173.71 (-0.19%)
NVDA   165.24 (+2.51%)
NIO   13.49 (+7.23%)
BABA   92.94 (+5.22%)
AMD   70.42 (+0.40%)
T   19.33 (+0.16%)
MU   54.93 (+2.06%)
CGC   3.22 (-0.62%)
F   13.15 (+0.38%)
GE   85.34 (+0.40%)
DIS   92.71 (+0.61%)
AMC   6.33 (+4.63%)
PYPL   75.03 (+0.82%)
PFE   50.52 (+0.56%)
NFLX   310.21 (+0.58%)
NASDAQ:TMDX

TransMedics Group - TMDX Stock Forecast, Price & News

$61.67
+1.37 (+2.27%)
(As of 12/8/2022 10:08 AM ET)
Add
Compare
Today's Range
$60.18
$61.95
50-Day Range
$39.08
$64.29
52-Week Range
$10.00
$64.36
Volume
1,316 shs
Average Volume
364,827 shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.14

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
18.5% Downside
$49.14 Price Target
Short Interest
Healthy
6.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of TransMedics Group in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$5.19 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.30) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

958th out of 1,027 stocks

Electromedical Equipment Industry

22nd out of 23 stocks

TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

S&P 500 Component DexCom Set For Further Price, Earnings Growth (TMDX)
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $49.14
TransMedics Remains A Buy Heading Into Q3 Earnings
5 Analysts Have This to Say About TransMedics Group
10 Best-Performing Small-Cap Stocks of 2022
TransMedics Group, Inc. (TMDX)
4 Analysts Have This to Say About TransMedics Group
Analyst Ratings for TransMedics Group
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Company Calendar

Last Earnings
11/03/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.14
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$39.00
Forecasted Upside/Downside
-20.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-44,220,000.00
Pretax Margin
-58.69%

Debt

Sales & Book Value

Annual Sales
$30.26 million
Book Value
$2.44 per share

Miscellaneous

Free Float
29,147,000
Market Cap
$1.97 billion
Optionable
Not Optionable
Beta
1.61

Key Executives

  • Dr. Waleed H. Hassanein M.D.Dr. Waleed H. Hassanein M.D. (Age 54)
    Founder, Pres, MD, CEO & Director
    Comp: $992.42k
  • Mr. Stephen GordonMr. Stephen Gordon (Age 54)
    CFO. Treasurer & Sec.
    Comp: $529.32k
  • Dr. Tamer I. Khayal M.D.Dr. Tamer I. Khayal M.D. (Age 53)
    Chief Commercial Officer
    Comp: $551.37k
  • Ms. Miriam C. Provost Ph.D.
    VP of Global Regulatory Affairs
  • Ms. Laura Damme
    VP of Clinical Affairs
  • Mr. John F. CareyMr. John F. Carey (Age 57)
    VP of Operations
  • Mr. Mark Anderson
    Sr. Director of Technology Devel.
  • Ms. Susan Goodman
    VP of HR













TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2023?

7 Wall Street research analysts have issued 1 year price targets for TransMedics Group's shares. Their TMDX share price forecasts range from $39.00 to $63.00. On average, they anticipate the company's share price to reach $49.14 in the next year. This suggests that the stock has a possible downside of 18.5%.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2022?

TransMedics Group's stock was trading at $19.16 at the start of the year. Since then, TMDX shares have increased by 214.7% and is now trading at $60.30.
View the best growth stocks for 2022 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) released its quarterly earnings results on Thursday, November, 3rd. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.15. The firm had revenue of $25.68 million for the quarter, compared to the consensus estimate of $18.96 million. TransMedics Group had a negative trailing twelve-month return on equity of 46.03% and a negative net margin of 58.78%.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $75.66 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.89%), Macquarie Group Ltd. (5.48%), Vanguard Group Inc. (5.15%), Credit Suisse AG (3.65%), Lord Abbett & CO. LLC (2.42%) and State Street Corp (2.17%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $60.30.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $1.93 billion and generates $30.26 million in revenue each year. The company earns $-44,220,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 12/8/2022 by MarketBeat.com Staff